{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:04:30Z","timestamp":1784271870360,"version":"3.55.0"},"reference-count":61,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2026.0050","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T06:23:30Z","timestamp":1784269410000},"source":"Crossref","is-referenced-by-count":0,"title":["Thyroid cancer: Epidemiology, diagnosis, and treatment"],"prefix":"10.3238","author":[{"given":"Katharina","family":"Holzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria Florentine","family":"Koehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Bojunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Luster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef K.","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Eilsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"10.3238\/arztebl.m2026.0050_ref1","unstructured":"Krebs in Deutschland, Schilddr\u00fcsenkrebs www.krebsdaten.de\/Krebs\/DE\/Content\/Krebsarten\/Schilddruesenkrebs\/schilddruesenkrebs_node.html (last accessed on 4 July 2025)."},{"key":"10.3238\/arztebl.m2026.0050_ref2","doi-asserted-by":"crossref","unstructured":"Holzer K, Bartsch DK: [Nodular goiter]. Chirurg 2020; 91: 712\u20139","DOI":"10.1007\/s00104-020-01218-3"},{"key":"10.3238\/arztebl.m2026.0050_ref3","doi-asserted-by":"crossref","unstructured":"Ahn HS, Kim HJ, Welch HG: Korea\u2018s thyroid-cancer \u201eepidemic\u201c\u2014screening and overdiagnosis. N Engl J Med 2014; 371: 1765\u20137","DOI":"10.1056\/NEJMp1409841"},{"key":"10.3238\/arztebl.m2026.0050_ref4","doi-asserted-by":"crossref","unstructured":"Ghossein CA, Khimraj A, Dogan S, Xu B: Metastasis to the thyroid gland: A single-institution 16-year experience. Histopathology 2021; 78: 508\u201319","DOI":"10.1111\/his.14246"},{"key":"10.3238\/arztebl.m2026.0050_ref5","doi-asserted-by":"crossref","unstructured":"Hisan UK, Myung SK, Nguyen GV: Associations between obesity and risk of thyroid cancer: A meta-analysis of cohort studies. Nutr Cancer 2025; 77: 288\u201398","DOI":"10.1080\/01635581.2024.2419488"},{"key":"10.3238\/arztebl.m2026.0050_ref6","doi-asserted-by":"crossref","unstructured":"Lee JH, Chai YJ, Yi KH: Effect of cigarette smoking on thyroid cancer: Meta-analysis. Endocrinol Metab (Seoul) 2021; 36: 590\u20138","DOI":"10.3803\/EnM.2021.954"},{"key":"10.3238\/arztebl.m2026.0050_ref7","doi-asserted-by":"crossref","unstructured":"Wang X, Cheng W, Li J, Zhu J: A meta-analysis of alcohol consumption and thyroid cancer risk. Oncotarget 2016; 7: 55912\u201323","DOI":"10.18632\/oncotarget.10352"},{"key":"10.3238\/arztebl.m2026.0050_ref8","doi-asserted-by":"crossref","unstructured":"Prabhash K, Saldanha E, Patil V, et al.: RET alterations differentiate molecular profile of medullary thyroid cancer. JCO Precis Oncol 2024; 8: e2300622","DOI":"10.1200\/PO.23.00622"},{"key":"10.3238\/arztebl.m2026.0050_ref9","doi-asserted-by":"crossref","unstructured":"Baloch ZW, Asa SL, Barletta JA, et al.: Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol 2022; 33: 27\u201363","DOI":"10.1007\/s12022-022-09707-3"},{"key":"10.3238\/arztebl.m2026.0050_ref10","doi-asserted-by":"crossref","unstructured":"Ma ZF, Skeaff SA: Thyroglobulin as a biomarker of iodine deficiency: A review. Thyroid 2014; 24: 1195\u2013209","DOI":"10.1089\/thy.2014.0052"},{"key":"10.3238\/arztebl.m2026.0050_ref11","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Schilddr\u00fcsenkarzinom, Langversion 1.01, 2025, AWMF-Registernummer: 031 056OL www.leitlinienprogramm-onkologie.de\/leitlinien\/schilddruesenkarzinom (last accessed on 26 July 2025)."},{"key":"10.3238\/arztebl.m2026.0050_ref12","doi-asserted-by":"crossref","unstructured":"Lorenz K, Machens A, Dralle H: Update Medull\u00e4res Schilddr\u00fcsenkarzinom \u2013 Was ist f\u00fcr Chirurg*innen relevant? Chirurgie 2025; 96: 551\u201360","DOI":"10.1007\/s00104-025-02289-w"},{"key":"10.3238\/arztebl.m2026.0050_ref13","doi-asserted-by":"crossref","unstructured":"Gharib H, Papini E, Garber JR, et al.: American association of clinical endocrinologists, American college of endocrinology, and associazione medici endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules\u20142016 update. Endocr Pract 2016; 22: 622\u201339","DOI":"10.4158\/EP161208.GL"},{"key":"10.3238\/arztebl.m2026.0050_ref14","doi-asserted-by":"crossref","unstructured":"Haugen BR, Alexander EK, Bible KC, et al.: 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26: 1\u2013133","DOI":"10.1089\/thy.2015.0020"},{"key":"10.3238\/arztebl.m2026.0050_ref15","doi-asserted-by":"crossref","unstructured":"Tessler FN, Middleton WD, Grant EG, et al.: ACR thyroid imaging, reporting and data system (TI-RADS): White paper of the ACR TI-RADS committee. J Am Coll Radiol 2017; 14: 587\u201395","DOI":"10.1016\/j.jacr.2017.01.046"},{"key":"10.3238\/arztebl.m2026.0050_ref16","doi-asserted-by":"crossref","unstructured":"Brito JP, Gionfriddo MR, Al Nofal A, et al.: The accuracy of thyroid nodule ultrasound to predict thyroid cancer: Systematic review and meta-analysis. J Clin Endocrinol Metab 2014; 99: 1253\u201363","DOI":"10.1210\/jc.2013-2928"},{"key":"10.3238\/arztebl.m2026.0050_ref17","doi-asserted-by":"crossref","unstructured":"Friedrich-Rust M, Vorlaender C, Dietrich CF, et al.: Evaluation of strain elastography for differentiation of thyroid nodules: Results of a prospective DEGUM multicenter study. Ultraschall Med 2016; 37: 262\u201370","DOI":"10.1055\/s-0042-104647"},{"key":"10.3238\/arztebl.m2026.0050_ref18","doi-asserted-by":"crossref","unstructured":"Ali SZ, Baloch ZW, Cochand-Priollet B, Schmitt FC, Vielh P, VanderLaan PA: The 2023 bethesda system for reporting thyroid cytopathology. Thyroid 2023; 33: 1039\u201344","DOI":"10.1089\/thy.2023.0141"},{"key":"10.3238\/arztebl.m2026.0050_ref19","doi-asserted-by":"crossref","unstructured":"Miyauchi A, Ito Y, Fujishima M, et al.: Long-term outcomes of active surveillance and immediate surgery for adult patients with low-risk papillary thyroid microcarcinoma: 30-year experience. Thyroid 2023; 33: 817\u201325","DOI":"10.1089\/thy.2023.0076"},{"key":"10.3238\/arztebl.m2026.0050_ref20","doi-asserted-by":"crossref","unstructured":"Machens A, Kaatzsch P, Lorenz K, et al.: Abandoning node dissection for desmoplasia-negative encapsulated unifocal sporadic medullary thyroid cancer. Surgery 2022; 171: 360\u20137","DOI":"10.1016\/j.surg.2021.07.035"},{"key":"10.3238\/arztebl.m2026.0050_ref21","doi-asserted-by":"crossref","unstructured":"Wang JR, Zafereo ME, Dadu R, et al.: Complete surgical resection following neoadjuvant Dabrafenib plus Trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma. Thyroid 2019; 29: 1036\u201343","DOI":"10.1089\/thy.2019.0133"},{"key":"10.3238\/arztebl.m2026.0050_ref22","doi-asserted-by":"crossref","unstructured":"Maurer E, Eilsberger F, W\u00e4chter S, et al.: Mutation-based, short-term \u201eneoadjuvant\u201c treatment allows resectability in stage IVB and C anaplastic thyroid cancer. Eur Arch Otorhinolaryngol 2023; 280: 1509\u201318","DOI":"10.1007\/s00405-023-07827-y"},{"key":"10.3238\/arztebl.m2026.0050_ref23","doi-asserted-by":"crossref","unstructured":"Verburg FA, Flux G, Giovanella L, van Nostrand D, Muylle K, Luster M: Differentiated thyroid cancer patients potentially benefitting from postoperative I-131 therapy: A review of the literature of the past decade. Eur J Nucl Med Mol Imaging 2020; 47: 78\u201383","DOI":"10.1007\/s00259-019-04479-1"},{"key":"10.3238\/arztebl.m2026.0050_ref24","doi-asserted-by":"crossref","unstructured":"Leboulleux S, Bournaud C, Chougnet CN, et al.: Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial. Lancet Diabetes Endocrinol 2025; 13: 38\u201346","DOI":"10.1016\/S2213-8587(24)00276-6"},{"key":"10.3238\/arztebl.m2026.0050_ref25","doi-asserted-by":"crossref","unstructured":"Mallick U, Newbold K, Beasley M, et al: Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN): A randomised, multicentre, non-inferiority trial. Lancet 2025; 406: 52\u201362","DOI":"10.1016\/S0140-6736(25)00629-4"},{"key":"10.3238\/arztebl.m2026.0050_ref26","doi-asserted-by":"crossref","unstructured":"Busaidy NL, Konda B, Wei L, et al.: Dabrafenib versus Dabrafenib + Trametinib in BRAF-Mutated radioactive iodine refractory differentiated thyroid cancer: Results of a randomized, phase 2, open-label multicenter trial. Thyroid 2022; 32: 1184\u201392","DOI":"10.1089\/thy.2022.0115"},{"key":"10.3238\/arztebl.m2026.0050_ref27","doi-asserted-by":"crossref","unstructured":"Leboulleux S, Do Cao C, Zerdoud S, et al.: A phase II redifferentiation trial with Dabrafenib-Trametinib and 131I in metastatic radioactive iodine refractory BRAF p.V600E-mutated differentiated thyroid cancer. Clin Cancer Res 2023; 29: 2401\u201309","DOI":"10.1158\/1078-0432.CCR-23-0046"},{"key":"10.3238\/arztebl.m2026.0050_ref28","doi-asserted-by":"crossref","unstructured":"Brose MS, Nutting CM, Jarzab B, et al.: Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. Lancet 2014; 384 (9940): 319\u201328","DOI":"10.1016\/S0140-6736(14)60421-9"},{"key":"10.3238\/arztebl.m2026.0050_ref29","doi-asserted-by":"crossref","unstructured":"Schlumberger M, Tahara M, Wirth LJ, et al.: Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015; 372: 621\u201330","DOI":"10.1056\/NEJMoa1406470"},{"key":"10.3238\/arztebl.m2026.0050_ref30","doi-asserted-by":"crossref","unstructured":"Koehler VF, Berg E, Adam P, et al.: Real-world efficacy and safety of multi-tyrosine kinase inhibitors in radioiodine refractory thyroid cancer. Thyroid 2021; 31: 1531\u201341","DOI":"10.1089\/thy.2021.0091"},{"key":"10.3238\/arztebl.m2026.0050_ref31","doi-asserted-by":"crossref","unstructured":"Brose MS, Robinson B, Sherman SI, et al.: Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2021; 22: 1126\u201338","DOI":"10.1016\/S1470-2045(21)00332-6"},{"key":"10.3238\/arztebl.m2026.0050_ref32","doi-asserted-by":"crossref","unstructured":"Wirth LJ, Sherman E, Robinson B, et al.: Efficacy of Selpercatinib in RET-altered thyroid cancers. N Engl J Med 2020; 383: 825\u201335","DOI":"10.1056\/NEJMoa2005651"},{"key":"10.3238\/arztebl.m2026.0050_ref33","doi-asserted-by":"crossref","unstructured":"Waguespack SG, Drilon A, Lin JJ, et al.: Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol 2022; 186: 631\u201343","DOI":"10.1530\/EJE-21-1259"},{"key":"10.3238\/arztebl.m2026.0050_ref34","doi-asserted-by":"crossref","unstructured":"Elisei R, Schlumberger MJ, M\u00fcller SP, et al.: Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013; 31: 3639\u201346","DOI":"10.1200\/JCO.2012.48.4659"},{"key":"10.3238\/arztebl.m2026.0050_ref35","doi-asserted-by":"crossref","unstructured":"Wells SA Jr, Robinson BG, Gagel RF, et al.: Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. J Clin Oncol 2012; 30: 134\u201341","DOI":"10.1200\/JCO.2011.35.5040"},{"key":"10.3238\/arztebl.m2026.0050_ref36","doi-asserted-by":"crossref","unstructured":"Hadoux J, Elisei R, Brose MS, et al.: Phase 3 trial of Selpercatinib in advanced RET-mutant medullary thyroid cancer. N Engl J Med 2023; 389: 1851\u201361","DOI":"10.1056\/NEJMoa2309719"},{"key":"10.3238\/arztebl.m2026.0050_ref37","doi-asserted-by":"crossref","unstructured":"Tiedje V, Stuschke M, Weber F, et al.: Anaplastic thyroid carcinoma: Review of treatment protocols. Endocr Relat Cancer 2018; 25: R153\u2013R61","DOI":"10.1530\/ERC-17-0435"},{"key":"10.3238\/arztebl.m2026.0050_ref38","doi-asserted-by":"crossref","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, et al.: Dabrafenib and Trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol 2018; 36: 7\u201313","DOI":"10.1200\/JCO.2017.73.6785"},{"key":"10.3238\/arztebl.m2026.0050_ref39","doi-asserted-by":"crossref","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, et al.: Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: The phase 2 ROAR trial. Nat Med 2023; 29: 1103\u201312","DOI":"10.1038\/s41591-023-02321-8"},{"key":"10.3238\/arztebl.m2026.0050_ref40","doi-asserted-by":"crossref","unstructured":"Dierks C, Seufert J, Aumann K, et al.: Combination of Lenvatinib and Pembrolizumab is an effective treatment option for anaplastic and Thyroid 2021; 31: 1076\u201385","DOI":"10.1089\/thy.2020.0322"},{"key":"10.3238\/arztebl.m2026.0050_ref41","doi-asserted-by":"crossref","unstructured":"Meisinger C, Ittermann T, Wallaschofski H, et al.: Geographic variations in the frequency of thyroid disorders and thyroid peroxidase antibodies in persons without former thyroid disease within Germany. Eur J Endocrinol 2012; 167: 363\u201371","DOI":"10.1530\/EJE-12-0111"},{"key":"10.3238\/arztebl.m2026.0050_ref42","doi-asserted-by":"crossref","unstructured":"Reiners C, Wegscheider K, Schicha H, et al.: Prevalence of thyroid disorders in the working population of Germany: Ultrasonography screening in 96,278 unselected employees. Thyroid 2004;14: 926\u201332","DOI":"10.1089\/thy.2004.14.926"},{"key":"10.3238\/arztebl.m2026.0050_ref43","doi-asserted-by":"crossref","unstructured":"Bartsch DK, Dotzenrath C, Vorl\u00e4nder C, et al.: Current practice of surgery for benign goitre-an analysis of the prospective DGAV StuDoQ|Thyroid Registry. J Clin Med 2019; 8: 477","DOI":"10.3390\/jcm8040477"},{"key":"10.3238\/arztebl.m2026.0050_ref44","unstructured":"Trupka A: Nicht-epitheliale Schilddr\u00fcsentumore und Metastasen. in Viszeral- und Allgemeinchirurgie, Springer Berlin, Heidelberg; www.doi.org\/10.1007\/978-3-662-61724-3."},{"key":"10.3238\/arztebl.m2026.0050_ref45","doi-asserted-by":"crossref","unstructured":"Suzuki K, Mitsutake N, Saenko V, Yamashita S: Radiation signatures in childhood thyroid cancers after the Chernobyl accident: Possible roles of radiation in carcinogenesis. Cancer Sci 2015; 106: 127\u201333","DOI":"10.1111\/cas.12583"},{"key":"10.3238\/arztebl.m2026.0050_ref46","doi-asserted-by":"crossref","unstructured":"Suter WR, Fantin AC, Meyenberger C: Diarrhoe als Erstmanifestation eines medull\u00e4ren Schilddr\u00fcsenkarzinoms. Dtsch Med Wochenschr 1998; 123: 1134\u20138","DOI":"10.1055\/s-2007-1024135"},{"key":"10.3238\/arztebl.m2026.0050_ref47","doi-asserted-by":"crossref","unstructured":"Wells SA Jr, Asa SL, Dralle H, et al.: Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015; 25: 567\u2013610","DOI":"10.1089\/thy.2014.0335"},{"key":"10.3238\/arztebl.m2026.0050_ref48","unstructured":"S1-Leitlinie Schilddr\u00fcsenszintigraphie mit Tc-99m Pertechnetat und I-123 Natriumiodid, AWMF Registernummer 031\u2013011, Stand 07\/2022."},{"key":"10.3238\/arztebl.m2026.0050_ref49","doi-asserted-by":"crossref","unstructured":"Kim H, Kim J, Son E, et al.: Preoperative prediction of the extrathyroidal extension of papillary thyroid carcinoma with ultrasonography versus MRI: A retrospective cohort study. Int J Surg 2014; 12: 544\u20138","DOI":"10.1016\/j.ijsu.2014.03.003"},{"key":"10.3238\/arztebl.m2026.0050_ref50","doi-asserted-by":"crossref","unstructured":"Goldner WS, Angell TE, McAdoo SL, et al.: Molecular variants and their risks for malignancy in cytologically indeterminate thyroid nodules. Thyroid 2019; 29: 1594\u20131605","DOI":"10.1089\/thy.2019.0278"},{"key":"10.3238\/arztebl.m2026.0050_ref51","doi-asserted-by":"crossref","unstructured":"Scheuba C, Kaserer K, Kaczirek K, Asari R, Niederle B: Desmoplastic stromal reaction in medullary thyroid cancer\u2014an intraoperative \u201emarker\u201c for lymph node metastases. World J Surg 2006; 30: 853\u20139","DOI":"10.1007\/s00268-005-0391-4"},{"key":"10.3238\/arztebl.m2026.0050_ref52","doi-asserted-by":"crossref","unstructured":"Schneider R, Machens A, Sekulla C, Lorenz K, Elwerr M, Dralle H: Superiority of continuous over intermittent intraoperative nerve monitoring in preventing vocal cord palsy. Br J Surg 2021; 108: 566\u201373","DOI":"10.1002\/bjs.11901"},{"key":"10.3238\/arztebl.m2026.0050_ref53","doi-asserted-by":"crossref","unstructured":"Barczyński M, Konturek A, Cichoń S: Randomized clinical trial of visualization versus neuromonitoring of recurrent laryngeal nerves during thyroidectomy. Br J Surg 2009; 96: 240\u20136","DOI":"10.1002\/bjs.6417"},{"key":"10.3238\/arztebl.m2026.0050_ref54","doi-asserted-by":"crossref","unstructured":"Thomusch O, Machens A, Sekulla C, Ukkat J, Brauckhoff M, Dralle H: The impact of surgical technique on postoperative hypoparathyroidism in bilateral thyroid surgery: A multivariate analysis of 5846 consecutive patients. Surgery 2003; 133: 180\u20135","DOI":"10.1067\/msy.2003.61"},{"key":"10.3238\/arztebl.m2026.0050_ref55","doi-asserted-by":"crossref","unstructured":"Ladurner R, Lerchenberger M, Al Arabi N, Gallwas JKS, Stepp H, Hallfeldt KKJ: Parathyroid autofluorescence-how does it affect parathyroid and thyroid surgery? A 5 year experience. Molecules 2019; 24: 2560","DOI":"10.3390\/molecules24142560"},{"key":"10.3238\/arztebl.m2026.0050_ref56","doi-asserted-by":"crossref","unstructured":"W\u00e4chter S, Bartsch DK: Update anaplastisches Schilddr\u00fcsenkarzinom \u2013 Was ist f\u00fcr Chirurg*innen relevant? Die Chirurgie 2025; 96: 561\u20137","DOI":"10.1007\/s00104-025-02277-0"},{"key":"10.3238\/arztebl.m2026.0050_ref57","doi-asserted-by":"crossref","unstructured":"Dierks C, Ruf J, Seufert J, et al.: 1646MO Phase II ATLEP trial: Final results for lenvatinib\/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma. Annals of Oncology 2022; 33 (Suppl 7): S1295","DOI":"10.1016\/j.annonc.2022.07.1726"},{"key":"10.3238\/arztebl.m2026.0050_ref58","doi-asserted-by":"crossref","unstructured":"Song E, Han M, Oh HS, et al.: Lobectomy is feasible for 1\u20134\u00a0cm papillary thyroid carcinomas: A 10-year propensity score matched-pair analysis on recurrence. Thyroid 2019; 29: 64\u201370","DOI":"10.1089\/thy.2018.0554"},{"key":"10.3238\/arztebl.m2026.0050_ref59","doi-asserted-by":"crossref","unstructured":"Vargas-Pinto S, Romero Arenas MA: Lobectomy compared to total thyroidectomy for low-risk papillary thyroid cancer: A systematic review. J Surg Res 2019; 242: 244\u201351","DOI":"10.1016\/j.jss.2019.04.036"},{"key":"10.3238\/arztebl.m2026.0050_ref60","doi-asserted-by":"crossref","unstructured":"Cabanillas ME, Dadu R, Ferrarotto R, et al.: Anti-programmed death ligand 1 plus targeted therapy in anaplastic thyroid carcinoma: A nonrandomized clinical trial. JAMA Oncol 2024; 10: 1672\u201380","DOI":"10.1001\/jamaoncol.2024.4729"},{"key":"10.3238\/arztebl.m2026.0050_ref61","doi-asserted-by":"crossref","unstructured":"Sehgal K, Pappa T, Shin KY, et al.: Dual immune checkpoint inhibition in patients with aggressive thyroid carcinoma: A phase 2 nonrandomized clinical trial. JAMA Oncol 2024; 10: 1663\u201371","DOI":"10.1001\/jamaoncol.2024.4019"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2026.0050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T06:23:59Z","timestamp":1784269439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2026.0050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":61,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2026.0050","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]}}}